Dewpoint scientific founder Tony Hyman elected to the Leopoldina National Academy of Sciences
Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]
Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]
BOSTON, June 16, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Michael Wagner, Ph.D., as Senior […]
BOSTON, April 21, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Isaac Klein, M.D., Ph.D., as Chief […]
A new article focused on fluorescence methods to characterize biomolecular condensates was published in Methods in Microbiology. The article, co-authored […]
BOSTON, March 9, 2021 – Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates […]
BOSTON, February 16, 2021 – Dewpoint Therapeutics, the biomolecular condensates company, today announced that it has appointed Regina Barzilay, Ph.D., to its […]
BOSTON, February 11, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer […]
A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]
BOSTON, January 6, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) […]
BOSTON, December 9, 2020 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Kara Carter, Ph.D., as Senior […]
Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science